the aids vaccine policy agenda
DESCRIPTION
The AIDS Vaccine Policy Agenda. Holly J. Wong Vice President, Public Policy International AIDS Vaccine Initiative (IAVI). Vienna, Austria International AIDS Society Conference July 18, 2010. A Time of Unprecedented Scientific Progress…. And Fiscal Constraint. - PowerPoint PPT PresentationTRANSCRIPT
The AIDS Vaccine Policy Agenda
Holly J. WongVice President, Public Policy
International AIDS Vaccine Initiative (IAVI)
Vienna, AustriaInternational AIDS Society Conference
July 18, 2010
A Time of Unprecedented Scientific Progress…And Fiscal Constraint
Policy Priorities in this Climate
To sustain an enabling environment for continued AIDS vaccine innovation
Identifying and addressing obstacles to scientific innovation
Developing new financing and incentive mechanisms for global health R&D
Demonstrating the value of an AIDS vaccine; advocating for strengthened political and financial support
Harnessing AIDS vaccine investments for economic development
Identifying and Addressing Obstacles to Scientific Innovation
Obstacles Recommendations
Product development capacity is limited
Stimulate capacity through innovative public investment
strategies targeting public and private producers
Excessive regulatory review times andmultiple conflicting regulatory requirements slow product development
Decrease review times through enhanced
administrative support;
Catalogue and disseminate regulatory requirements
Enhancing Brazil’s Capacity for Biopharmaceutical Innovation
Brazilian STD, AIDS and Hepatitis Department
Chinese Ministry of Health
Urgent need to accelerate AIDS vaccine R&D
Need for innovative approaches and new thinking
??
?
The state of the AIDS vaccine field
Establish a community of solvers
Accelerate the time it takes to solve the problem;
Allow for multiple approaches to achieve the same goal
Prize competitions could…
Generate excitement and publicity and elevate the profile of the field;
Cast a wide net to attract participants from outside the field of interest;
Identifying and Addressing Obstacles to Scientific Innovation
Urgent need to accelerate AIDS vaccine R&D
Demonstrating the Value of an AIDS Vaccine
Key findings:
Even with full scale-up of existing prevention and treatment, new HIV infections will persist in developing countries
An AIDS vaccine with 50% efficacy given to 30% of the adult population would avert 24% of new infections 2015-2030, or 5.6 million
Preliminary findings suggest that an AIDS vaccine would be cost saving.
Potential Impact of an AIDS Vaccine in Developing Countries
Makerere Univ. School of Public Health
Kenya AIDS Vaccine Initiative
Evandro Chagas Clinical Research Inst.
Traditional funding for AIDS vaccine R&D is:
Insufficient Unpredictable Inflexible Short-term
New financing mechanisms could be designed to bring additional resources and accelerate global health R&D by:
Accessing funding from untapped resources
Mitigating political and economic shocks
Making future economic value of products available now
Supporting scientific risk-taking
Creating flexibility to facilitate rapid change of direction as new science emerges
Developing New Financing Mechanisms to Advance Global Health R&D
Policy priorities:
Develop a financing mechanism for global health R&D, or AIDS vaccine R&D
Expand existing mechanisms to include R&D
Investments in AIDS vaccine R&D can contribute to broader economic development goals:
In the longer term: by reducing disease burdens, increasing workforce productivity
In the near term: collaborative research with developing country partners can strengthen capacities for science and technology, contributing to growth and diversification of jobs, firms, and economies
Harnessing AIDS Vaccine Investments for Economic Development
Policy priority in this area:
Identify and advocate for best practices in maximizing development impact of global health R&D investments
Advocating for Strengthened Political and Financial Support
Policy Advocacy Priorities:
Tracking available resources for AIDS vaccine R&D to make the case for increased and diversified investment
Demonstrating the spillover benefits of AIDS vaccine investment on development and health systems strengthening
Positioning AIDS vaccines as a tool to help achieve universal access and the MDGs
Annual Investments in HIV Vaccine R&D 2000-2009U
S$ M
illio
ns
Conclusions At a time of scientific progress and
fiscal constraint, it is critical to sustain and increase political and financial support to continue advancing AIDS vaccine science.
Policy reforms are key to creating an
enabling environment to accelerate AIDS vaccine R&D.
Identifying new funders and developing new R&D financing mechanisms are urgent priorities
Policies to spur scientific innovation and engage the private sector are also key priorities to accelerate aids vaccine science